DDInter518 DDInter899
Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was withdrawn.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Dexfenfluramine {u} may lead to a major life threatening interaction when taken with {v} Metamfetamine
Dexfenfluramine {u} (Compound) resembles {v} (Compound) Fenproporex
Dexfenfluramine {u} (Compound) binds {v} (Gene) SLC6A4
Dexfenfluramine {u} (Compound) upregulates {v} (Gene) ARL4C
Dexfenfluramine {u} (Compound) downregulates {v} (Gene) TIMM9
Dexfenfluramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tolterodine
Dexfenfluramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dacomitinib
Dexfenfluramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pioglitazone
Dexfenfluramine {u} may lead to a major life threatening interaction when taken with {v} Sibutramine
Dexfenfluramine may lead to a major life threatening interaction when taken with Metamfetamine
Dexfenfluramine (Compound) resembles Fenproporex (Compound)
Dexfenfluramine (Compound) binds SLC6A4 (Gene)
Dexfenfluramine (Compound) upregulates ARL4C (Gene)
Dexfenfluramine (Compound) downregulates TIMM9 (Gene)
Dexfenfluramine may cause a minor interaction that can limit clinical effects when taken with Tolterodine
Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib
Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone
Dexfenfluramine may lead to a major life threatening interaction when taken with Sibutramine